London UK, 10th July 2013: Vasgen Limited (“Vasgen” or “the Company”), a new speciality biotech company, reports its participation at the inaugural ON Helix Conference.
Organised by One Nucleus, the conference brought various stakeholders engaged in translational research to discuss ways to drive UK innovation. Dr Salman Rahman, CEO and co-founder of Vasgen said: “We were pleased to attend ON Helix and learn about previous UK successes in translating biomedical research and to hear about some of the emerging technologies in this arena. The conference also provided us with an opportunity to meet potential sponsors, clients and partners with shared interests.”
-Ends-
Notes to Editors
Vasgen limited is a new London-based biotech company developing innovative ocular and cancer therapeutics to meet unmet clinical needs. The Company’s technologies include AbIMPTM, a novel antibody-based approach allowing development of highly selective inhibitors of metalloproteinase catalytic activity with a particular focus on the ADAMs gene family of sheddases. The Company’s lead product under development is a pre-clinical stage therapeutic AbIMP targeting ADAM15 for anti-angiogenesis therapy. More information is available at www.vasgen.co.uk
For further information please contact:
Tel : +44 (0)207 691 2149
info@vasgen.co.uk